Coder-rony commited on
Commit
c1b9bfb
·
verified ·
1 Parent(s): 62941e7

raw shard 362

Browse files
Files changed (1) hide show
  1. raw/shard_00362.jsonl +5 -0
raw/shard_00362.jsonl ADDED
@@ -0,0 +1,5 @@
 
 
 
 
 
 
1
+ {"session_id": "atlas-5e20dca1dc", "tier": "text", "task_instruction": "Understand the role of chromosomal translocations in AML development and prognosis.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "AML is associated with various chromosomal abnormalities which can influence prognosis.", "image_path": null, "audio_path": null}, "reasoning": "The presence of specific cytogenetic abnormalities in AML patients suggests that these genetic changes play a significant role in the disease's progression and outcome. Chromosomal translocations are a common type of abnormality, where parts of chromosomes break and rejoin incorrectly, leading to the formation of fusion proteins.", "action": {"type": "text_response", "value": "Identify the types of chromosomal translocations and their associated fusion proteins in AML."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "Chromosomal translocations produce abnormal fusion proteins, often transcription factors.", "image_path": null, "audio_path": null}, "reasoning": "These fusion proteins result from the incorrect joining of genes due to translocations. For example, in acute promyelocytic leukemia, the t(15;17) translocation creates a PML-RARα fusion protein. This protein is a transcription factor that interferes with normal gene expression in myeloid cells.", "action": {"type": "text_response", "value": "Examine how these fusion proteins affect myeloid differentiation and the overall prognosis."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "The PML-RARα fusion protein inhibits myeloid differentiation by binding to retinoic acid receptor elements.", "image_path": null, "audio_path": null}, "reasoning": "The fusion protein binds to specific DNA elements in the promoters of myeloid genes, preventing the activation of these genes. This leads to 'differentiation arrest,' where the leukemia cells fail to mature into healthy blood cells, contributing to the progression of the disease.", "action": {"type": "text_response", "value": "Understand the mechanism by which these fusion proteins cause leukemia and how this impacts treatment and prognosis."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "Differentiation arrest is a key mechanism in AML pathogenesis.", "image_path": null, "audio_path": null}, "reasoning": "When myeloid cells cannot differentiate properly, they remain in an immature state, leading to the accumulation of abnormal cells in the bone marrow and bloodstream. This failure to differentiate is a critical factor in the development and prognosis of AML, as it hinders normal blood cell production and contributes to the disease's severity.", "action": {"type": "text_response", "value": "Explore how targeting these fusion proteins or their effects could lead to new treatment strategies for AML."}, "refers_back_to": null}], "task_complexity": "high", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "Specific cytogenetic abnormalities can be found in many people with AML ; the types of chromosomal abnormalities often have prognostic significance . The chromosomal translocations encode abnormal fusion proteins , usually transcription factors whose altered properties may cause the \" differentiation arrest \" . For example , in acute promyelocytic leukemia , the t ( 15 ; 17 ) translocation produces a PML @-@ RARα fusion protein which binds to the retinoic acid receptor element in the promoters of several myeloid @-@ specific genes and inhibits myeloid differentiation ."}
2
+ {"session_id": "atlas-7b74defaa7", "tier": "text", "task_instruction": "Identify the symptoms of AML and explain their causes.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "AML affects the bone marrow.", "image_path": null, "audio_path": null}, "reasoning": "Leukemic clone cells grow and interfere with normal blood cell development.", "action": {"type": "text_response", "value": "This leads to reduced production of normal blood cells."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "Normal blood cells are reduced.", "image_path": null, "audio_path": null}, "reasoning": "This results in conditions like neutropenia, anemia, and thrombocytopenia.", "action": {"type": "text_response", "value": "These conditions are the primary symptoms of AML."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "In rare cases, chloroma can develop.", "image_path": null, "audio_path": null}, "reasoning": "Chloroma is a solid tumor of leukemic cells outside the bone marrow.", "action": {"type": "text_response", "value": "It can cause various symptoms depending on its location."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "The clinical signs and symptoms of AML result from the growth of leukemic clone cells , which tends to displace or interfere with the development of normal blood cells in the bone marrow . This leads to neutropenia , anemia , and thrombocytopenia . The symptoms of AML are , in turn , often due to the low numbers of these normal blood elements . In rare cases , people with AML can develop a chloroma , or solid tumor of leukemic cells outside the bone marrow , which can cause various symptoms depending on its location ."}
3
+ {"session_id": "atlas-398edf3e3c", "tier": "text", "task_instruction": "Understand how genetic mutations contribute to AML through epigenetic changes.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "Genetic mutations affect enzymes like TET2, IDH1, and IDH2.", "image_path": null, "audio_path": null}, "reasoning": "These enzymes are involved in epigenetic regulation and metabolism. Mutations can alter their function, leading to changes in gene expression and potentially oncogenesis.", "action": {"type": "text_response", "value": "Identify the specific enzymes and their roles in epigenetic regulation and metabolism."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "TET2 is a DNA demethylase and its inhibition leads to gene silencing.", "image_path": null, "audio_path": null}, "reasoning": "Demethylases remove methyl groups, which typically activate gene expression. If TET2 is inhibited, genes may become silenced, including tumor suppressors, contributing to leukemia development.", "action": {"type": "text_response", "value": "Understand the role of TET2 in gene expression and its inhibition in AML."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "IDH1 and IDH2 mutations generate D-2-hydroxyglutarate.", "image_path": null, "audio_path": null}, "reasoning": "This oncometabolite can inhibit epigenetic enzymes like TET2, creating a feedback loop that sustains epigenetic changes and promotes cancer progression.", "action": {"type": "text_response", "value": "Investigate how D-2-hydroxyglutarate affects TET2 activity and overall epigenetic regulation."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "Epigenetic mutations silence tumor suppressors or activate oncogenes.", "image_path": null, "audio_path": null}, "reasoning": "By altering the epigenetic landscape, these mutations can lead to the silencing of genes that prevent cancer (tumor suppressors) or activate genes that promote cancer (proto-oncogenes).", "action": {"type": "text_response", "value": "Analyze the mechanisms by which epigenetic mutations affect tumor suppressor and oncogene activity in AML."}, "refers_back_to": null}], "task_complexity": "high", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "An important pathophysiological mechanism of leukemogenesis in AML is the epigenetic induction of dedifferentiation by genetic mutations that alter the function of epigenetic enzymes , such as the DNA demethylase TET2 and the metabolic enzymes IDH1 and IDH2 , which lead to the generation of a novel oncometabolite , D @-@ 2 @-@ hydroxyglutarate , which inhibits the activity of epigenetic enzymes such as TET2 . The hypothesis is that such epigenetic mutations lead to the silencing of tumor suppressor genes and / or the activation of proto @-@ oncogenes ."}
4
+ {"session_id": "atlas-b16547b41e", "tier": "text", "task_instruction": "Understand the treatment phases and options for AML.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "AML treatment involves two main phases: induction and consolidation.", "image_path": null, "audio_path": null}, "reasoning": "The passage explains that first-line treatment for AML includes chemotherapy divided into induction and postremission therapy. Induction aims for complete remission, while consolidation targets residual disease.", "action": {"type": "text_response", "value": "Identify the two phases of initial chemotherapy treatment."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "Induction therapy aims to reduce leukemic cells to undetectable levels for complete remission.", "image_path": null, "audio_path": null}, "reasoning": "Induction is the first phase, focusing on achieving remission by significantly reducing the number of leukemia cells.", "action": {"type": "text_response", "value": "Understand the purpose of induction therapy."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "Consolidation therapy aims to eliminate any residual disease to achieve a cure.", "image_path": null, "audio_path": null}, "reasoning": "Following induction, consolidation therapy ensures that any remaining disease is eradicated, preventing relapse.", "action": {"type": "text_response", "value": "Understand the purpose of consolidation therapy."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "Hematopoietic stem cell transplantation is an alternative treatment option.", "image_path": null, "audio_path": null}, "reasoning": "Used if chemotherapy fails or for high-risk patients, stem cell transplantation offers another pathway for treatment.", "action": {"type": "text_response", "value": "Identify alternative treatments beyond chemotherapy."}, "refers_back_to": null}, {"step_index": 4, "observation": {"text": "Research is ongoing to incorporate tyrosine kinase inhibitors into AML treatment.", "image_path": null, "audio_path": null}, "reasoning": "The passage highlights that researchers are exploring new drugs like tyrosine kinase inhibitors for treatment.", "action": {"type": "text_response", "value": "Recognize current research efforts in AML treatment."}, "refers_back_to": null}], "task_complexity": "high", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "First @-@ line treatment of AML consists primarily of chemotherapy , and is divided into two phases : induction and postremission ( or consolidation ) therapy . The goal of induction therapy is to achieve a complete remission by reducing the number of leukemic cells to an undetectable level ; the goal of consolidation therapy is to eliminate any residual undetectable disease and achieve a cure . Hematopoietic stem cell transplantation is usually considered if induction chemotherapy fails or after a person relapses , although transplantation is also sometimes used as front @-@ line therapy for people with high @-@ risk disease . Efforts to use tyrosine kinase inhibitors in AML continue ."}
5
+ {"session_id": "atlas-cc60cdbf70", "tier": "text", "task_instruction": "Determine the most common induction chemotherapy regimen for AML and its components.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The passage discusses different induction regimens for AML.", "image_path": null, "audio_path": null}, "reasoning": "I need to identify the most common one mentioned.", "action": {"type": "text_response", "value": "Read through the passage to find the primary regimen."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "The passage states that '7 + 3' is the standard induction regimen.", "image_path": null, "audio_path": null}, "reasoning": "'7 + 3' refers to cytarabine and an anthracycline, typically daunorubicin.", "action": {"type": "text_response", "value": "Note the components of this regimen."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "Cytarabine is given as a continuous IV infusion for seven days.", "image_path": null, "audio_path": null}, "reasoning": "This is part of the '7 + 3' protocol.", "action": {"type": "text_response", "value": "Record the duration and method of administration for cytarabine."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "Anthracycline, usually daunorubicin, is given as an IV push for three days.", "image_path": null, "audio_path": null}, "reasoning": "This aligns with the '3 + 7' nomenclature.", "action": {"type": "text_response", "value": "Note the duration and method for the anthracycline."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-17", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "All FAB subtypes except M3 are usually given induction chemotherapy with cytarabine ( ara @-@ C ) and an anthracycline ( most often daunorubicin ) . This induction chemotherapy regimen is known as \" 7 + 3 \" ( or \" 3 + 7 \" ) , because the cytarabine is given as a continuous IV infusion for seven consecutive days while the anthracycline is given for three consecutive days as an IV push . Up to 70 % of people with AML will achieve a remission with this protocol . Other alternative induction regimens , including high @-@ dose cytarabine alone , FLAG @-@ like regimens or investigational agents , may also be used . Because of the toxic effects of therapy , including myelosuppression and an increased risk of infection , induction chemotherapy may not be offered to the very elderly , and the options may include less intense chemotherapy or palliative care ."}